{{Rsnum
|rsid=749292
|Gene=CYP19A1
|Chromosome=15
|position=51266534
|Orientation=plus
|GMAF=0.4307
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;G)
|geno3=(G;G)
|Gene_s=CYP19A1
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;G)
| geno3=(G;G)
| CEU | 23.0 | 45.1 | 31.9
| HCB | 21.9 | 55.5 | 22.6
| JPT | 15.0 | 46.9 | 38.1
| YRI | 27.2 | 46.3 | 26.5
| ASW | 17.5 | 56.1 | 26.3
| CHB | 21.9 | 55.5 | 22.6
| CHD | 28.4 | 43.1 | 28.4
| GIH | 15.8 | 43.6 | 40.6
| LWK | 18.2 | 40.9 | 40.9
| MEX | 10.3 | 55.2 | 34.5
| MKK | 16.0 | 44.2 | 39.7
| TSI | 14.7 | 44.1 | 41.2
| HapMapRevision=28
}}
{{PMID|18667686|OA=1
}} rs749292(A) associated with [[ovarian cancer]] risk in a codominant model for all races combined [AG versus AA genotype: odds ratio (OR), 1.48 and 95% confidence interval (CI), 1.07-2.04); GG versus AA: OR, 1.87 (CI, 1.24-2.82); Ptrend =0.002].

{{PMID|19124504|OA=1
}} [[endometrial cancer]] 
*rs749292(A) allele OR of 1.14, 95% confidence interval of 1.09-1.21, and P = 7.1 x 10(-7)
*rs727479(A) odds ratio per allele of 1.08, 95% confidence interval of 1.02-1.14, and P = 0.009

{{omim
|desc=CYTOCHROME P450, FAMILY 19, SUBFAMILY A, POLYPEPTIDE 1; CYP19A1
|id=107910
|rsnum=749292
}}
{{PMID Auto
|PMID=19789370
|Title=CYP19A1 Genetic Variation in Relation to Prostate Cancer Risk and Circulating Sex Hormone Concentrations in Men from the Breast and Prostate Cancer Cohort Consortium
|OA=1
}}

{{PMID Auto
|PMID=16733710
|Title=Association analyses of CYP19 gene polymorphisms with height variation in a large sample of Caucasian nuclear families.
|OA=1
}}

{{PMID Auto
|PMID=16782804
|Title=Polymorphisms of estrogen-biosynthesis genes CYP17 and CYP19 may influence age at menarche: a genetic association study in Caucasian females.
|OA=1
}}

{{PMID Auto
|PMID=16949385
|Title=Aromatase gene (CYP 19) polymorphisms and endogenous androgen concentrations in a multiracial/multiethnic, multisite study of women at midlife.
}}

{{PMID Auto
|PMID=16949394
|Title=Cognitive functioning and sex steroid hormone gene polymorphisms in women at midlife.
}}

{{PMID Auto
|PMID=17002564
|Title=Robust and comprehensive analysis of 20 osteoporosis candidate genes by very high-density single-nucleotide polymorphism screen among 405 white nuclear families identified significant association and gene-gene interaction.
|OA=1
}}

{{PMID Auto
|PMID=17325027
|Title=Genetic variation at the CYP19A1 locus predicts circulating estrogen levels but not breast cancer risk in postmenopausal women.
}}

{{PMID Auto
|PMID=18199708
|Title=Haplotype analyses of CYP19A1 gene variants and breast cancer risk: results from the Shanghai Breast Cancer Study.
|OA=1
}}

{{PMID Auto
|PMID=18622258
|Title=Association of genetic polymorphisms in CYP19A1 and blood levels of sex hormones among postmenopausal Chinese women.
|OA=1
}}

{{PMID Auto
|PMID=18941913
|Title=Coffee intake, variants in genes involved in caffeine metabolism, and the risk of epithelial ovarian cancer.
|OA=1
}}

{{PMID Auto
|PMID=19015200
|Title=Polymorphisms in estrogen- and androgen-metabolizing genes and the risk of gastric cancer.
|OA=1
}}

{{PMID Auto
|PMID=19064562
|Title=Genetic variation in CYP19A1 and risk of breast cancer and fibrocystic breast conditions among women in Shanghai, China.
|OA=1
}}

{{PMID Auto
|PMID=19630952
|Title=Sex steroid metabolism polymorphisms and mammographic density in pre- and early perimenopausal women.
|OA=1
}}

{{PMID Auto
|PMID=23129173
|Title=Plasma estrone sulfate concentrations and genetic variation at the CYP19A1 locus in postmenopausal women with early breast cancer treated with letrozole
|OA=1
}}

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Affy GenomeWide 6}}
{{on chip | FTDNA2}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}